Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Shanxi Taxus to Gain Control of Cardium with $5 Million Investment

publication date: Mar 6, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shanxi Taxus Pharma announced plans to take over Cardium Therapeutics of San Diego by purchasing $5 million of unregistered Cardium shares. Before the investment, Cardium had a market capitalization of $5 million. Cardium will use the money to continue development of two regenerative products. Taxus will help Cardium obtain approval of the products in China, and Cardium will return the favor by helping Taxus bring its Taxol-based drugs to the US. Cardium changed its name to Taxus Cardium after the investment. More details....

Stock Symbol: (OTC: CRXM)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...